Candel Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
CADL$9.35-1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| COMMON STOCK · TREASURY STOCK | |||||||
|---|---|---|---|---|---|---|---|
| SHARES | AMOUNT | SHARES | AMOUNT | ADDITIONALPAID-IN CAPITAL | ACCUMULATEDDEFICIT | STOCKHOLDERS’EQUITY | |
| Balance as of December 31, 2023 | 29,213,627 | $290 | (122,608) | $(448) | $149,931 | $(137,028) | $12,745 |
| Issuance of common stock and accompanying pre-funded warrants in public offering, net of issuance costs of $6.1 million | 12,000,001 | 120 | — | — | 85,808 | — | 85,928 |
| Sale of common stock through at-the-market offerings, net of issuance costs of $0.5 million | 2,936,057 | 29 | — | — | 15,801 | — | 15,830 |
| Options exercised | 846,943 | 9 | — | — | 1,680 | — | 1,689 |
| Stock-based compensation | — | — | — | — | 4,170 | — | 4,170 |
| Restricted stock unit vesting | 1,936,460 | 21 | — | — | (21) | — | — |
| Change in fair value of NC Ohio Trust Warrants | — | — | — | — | 1,142 | — | 1,142 |
| Net loss | — | — | — | — | — | (55,177) | (55,177) |
| Balance as of December 31, 2024 | 46,933,088 | $469 | (122,608) | $(448) | $258,511 | $(192,205) | $66,327 |
| Issuance of common stock in registered direct offering, net of issuance costs of $0.7 million | 3,221,395 | 32 | — | — | 14,299 | — | 14,331 |
| Sale of common stock through at-the-market offerings, net of issuance costs of $0.2 million | 987,772 | 10 | — | — | 5,028 | — | 5,038 |
| Options exercised | 219,813 | 3 | — | — | 513 | — | 516 |
| Stock-based compensation | — | — | — | — | 4,315 | — | 4,315 |
| Restricted stock unit vesting | 330,779 | 3 | — | — | (3) | — | — |
| Change in fair value of NC Ohio Trust Warrants | — | — | — | — | (498) | — | (498) |
| Exercise of pre-funded warrants | 3,328,064 | 33 | — | — | (33) | — | — |
| Issuance costs related to common stock and accompanying pre-funded warrants in public offering | — | — | — | — | 75 | — | 75 |
| Net loss | — | — | — | — | — | (38,182) | (38,182) |
| Balance as of December 31, 2025 | 55,020,911 | $550 | (122,608) | $(448) | $282,207 | $(230,387) | $51,922 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.